Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

A Phase I/II Study to Investigate the Addition of Venetoclax to Dasatinib and Steroids in Patients with Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL): The Venda Trial, in Progress

Jessica T. Leonard, Rachel Cook, Laura F. Newell, Arpita Gandhi, Ronan T. Swords, Christopher A. Eide, Brandon Hayes-Lattin, Kara Johnson, Elie Traer, Stephen E. Kurtz, Jennifer N. Saultz, Cristina Tognon, Jeffrey W Tyner, Curtis A. Lachowiez

Blood (2023) 142 (Supplement 1): 1512.

https://doi.org/10.1182/blood-2023-188313

Published: 2023

Journal Articles

Prognostic Significance of NCAM1 (CD56) Expression in AML Patients Treated with HMA+Venetoclax

Blood (2023) 142 (Supplement 1): 5762.

https://doi.org/10.1182/blood-2023-188311

Published: 2023

Journal Articles

Results of a Phase 1 Trial Testing the Novel Combination Therapy of Venetoclax and Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia Patients

Blood (2023) 142 (Supplement 1): 1515.

https://doi.org/10.1182/blood-2023-191166

Published: 2023

Journal Articles

Acute Myeloid Leukemia Differentiation State and Genotype Influence Anti-Apoptotic Protein Expression, Venetoclax Sensitivity, and Survival in AML

Blood (2023) 142 (Supplement 1): 978.

https://doi.org/10.1182/blood-2023-179527

Published: 2023

Journal Articles

Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients Enrolled in CPX-351-301, a Randomized Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk and/or Secondary AML

Geoffrey L Uy, MD, Laura F. Newell, MD, Tara Lin, MD, Stuart L. Goldberg, Matthew J. Wieduwilt, MD PhD, Robert J. Ryan, Stefan Faderl, Jeffrey E. Lancet, MD

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-136882

Published: 2020

Journal Articles

Phase 3 Exploratory Analysis of Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Received Consolidation with CPX-351 Versus Conventional Chemotherapy

Jonathan E. Kolitz, MD, Daniel H. Ryan, MD, Laura F. Newell, MD, Stephen A. Strickland, MD, Donna E. Hogge, MD PhD, Scott R. Solomon, MD, Gary J. Schiller, MD, Robert J. Ryan, MS, Stefan Faderl, MD, Jorge E. Cortes, MD

Blood (2019) 134 (Supplement_1): 3856.

https://doi.org/10.1182/blood-2019-124553

Published: 2019

Journal Articles

Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Analysis

Daniel H. Ryan, MD, Laura F. Newell, MD, Ellen K. Ritchie, MD, Stephen A. Strickland, MD, Donna E. Hogge, MD PhD, Scott R. Solomon, MD, Richard M. Stone, MD, Gary J. Schiller, MD, Matthew J. Wieduwilt, MD PhD, Robert J. Ryan, MS, Stefan Faderl, MD, Jorge E. Cortes, MD

Blood (2019) 134 (Supplement_1): 3842.

https://doi.org/10.1182/blood-2019-124516

Published: 2019

Journal Articles

Outcomes in Patients with Therapy-Related Acute Myeloid Leukemia (t-AML) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Analysis

Jeffrey E. Lancet, MD, David A. Rizzieri, MD, Gary J. Schiller, MD, Scott R. Solomon, MD, Laura F. Newell, MD, Harry P. Erba, MD PhD, Robert J. Ryan, MS, Stefan Faderl, MD, Jorge E. Cortes, MD

Blood (2019) 134 (Supplement_1): 1313.

https://doi.org/10.1182/blood-2019-124383

Published: 2019

Journal Articles

Feasibility and Cost Analysis of Day 4 Granulocyte Colony-Stimulating Factor Mobilized Peripheral Blood Progenitor Cell Collection from HLA-Matched Sibling Donors

Laura F. Newell, MD, Rebekah Knight, Kelsea Shoop, Sara Murray, Rogelyn Kwock, NP, Carol Jacoby, NP, Susan Slater, NP, Bryon Allen, NP, Brad Cota, MBA, Peggy Appel, Rachel J. Cook, MD, Richard T. Maziarz, MD, Gabrielle Meyers, MD

Blood (2018) 132 (Supplement 1): 4558.

https://doi.org/10.1182/blood-2018-99-120342

Published: 2018

Journal Articles

The Impact of Hematopoietic Cell Transplantation on Survival: An Exploratory Analysis of a Phase 3 Study of CPX-351 Versus 7+3 in Older Patients with Newly Diagnosed, High-Risk/Secondary AML

Tara L Lin, MD, Jorge E. Cortes, MD, Laura F. Newell, MD, Ellen K. Ritchie, MD, Robert K. Stuart, MD, Stephen A. Strickland, MD, Donna Hogge, Scott R Solomon, MD, Richard M. Stone, MD, Dale L. Bixby, MD PhD, Jonathan E. Kolitz, MD, Gary J. Schiller, MD, Matthew J. Wieduwilt, MD PhD, Daniel H. Ryan, Robert Ryan, Michael Chiarella, Arthur C. Louie, Geoffrey L. Uy, MD

Blood (2018) 132 (Supplement 1): 2706.

https://doi.org/10.1182/blood-2018-99-112557

Published: 2018

Journal Articles

Efficacy and Safety of CPX-351 Versus 7+3 in a Subgroup of Older Patients with Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Enrolled in a Phase 3 Study

Daniel H. Ryan, Geoffrey L. Uy, MD, Jorge E. Cortes, MD, Laura F. Newell, MD, Ellen K. Ritchie, MD, Robert K. Stuart, MD, Stephen A. Strickland, MD, Donna Hogge, Scott R Solomon, MD, Richard M. Stone, MD, Dale L. Bixby, MD PhD, Jonathan E. Kolitz, MD, Gary J. Schiller, MD, Matthew J. Wieduwilt, MD PhD, Robert Ryan, Michael Chiarella, Arthur C. Louie, Jeffrey E. Lancet, MD

Blood (2018) 132 (Supplement 1): 1425.

https://doi.org/10.1182/blood-2018-99-111514

Published: 2018

Journal Articles

Transcriptomal Evidence for Dysregulation of Angiogenic Factors and Inflammatory Markers after Allogeneic Hematopoietic Cell Transplantation

Laura F. Newell, MD, Kristina Vartanian, Christina A Harrington, PhD, Shernan G. Holtan, MD

Blood (2017) 130 (Supplement 1): 3259.

https://doi.org/10.1182/blood.V130.Suppl_1.3259.3259

Published: 2017

Journal Articles

Rates of Adverse Events per Patient-Year in a Randomized, Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, Treatment-Related Acute Myeloid Leukemia (AML) or AML with Myelodysplasia-Related Changes

Bruno C Medeiros, MD, Jeffrey E. Lancet, MD, Jorge E. Cortes, MD, Laura F. Newell, MD, Tara L. Lin, MD, Ellen K Ritchie, MD, Robert K. Stuart, MD, Stephen A. Strickland, MD MSCI, Donna Hogge, Scott R Solomon, MD, Richard M. Stone, MD, Dale L. Bixby, Jonathan E. Kolitz, MD, Gary J. Schiller, Matthew J. Wieduwilt, Robert J. Ryan, Michael Chiarella, Arthur C Louie, Geoffrey L. Uy, MD

Blood (2017) 130 (Supplement 1): 1366.

https://doi.org/10.1182/blood.V130.Suppl_1.1366.1366

Published: 2017

Journal Articles

Amphiregulin Improves Stratification of the Refined Minnesota Acute Graft-Versus-Host Disease Risk Score: Results from BMT CTN 0302/0802

Blood (2017) 130 (Supplement 1): 72.

https://doi.org/10.1182/blood.V130.Suppl_1.72.72

Published: 2017

Journal Articles

Efficacy and Safety of CPX-351 Versus 7+3 in Older Adults with Secondary Acute Myeloid Leukemia: Combined Subgroup Analysis of Phase 2 and Phase 3 Studies

Blood (2017) 130 (Supplement 1): 2657.

https://doi.org/10.1182/blood.V130.Suppl_1.2657.2657

Published: 2017

Journal Articles

Subanalysis of Patients with Secondary Acute Myeloid Leukemia (sAML) with Refractory Anemia with Excess of Blasts in Transformation (RAEB-t) Enrolled in a Phase 3 Study of CPX-351 Versus Conventional 7+3 Cytarabine and Daunorubicin

Tara L. Lin, MD, Geoffrey L. Uy, MD, Matthew J. Wieduwilt, Laura F. Newell, MD, Robert K. Stuart, MD, Bruno C Medeiros, MD, Gary J. Schiller, Eric Rubenstein, MD, Wendy Stock, MD, Erica D. Warlick, MD, Matthew Foster, Dale L. Bixby, Nikolai A. Podoltsev, MD PhD, Qi An, Stefan Faderl, Arthur C. Louie, Jeffrey E. Lancet, MD

Blood (2017) 130 (Supplement 1): 1698.

https://doi.org/10.1182/blood.V130.Suppl_1.1698.1698

Published: 2017

Journal Articles

Multivariate Efficacy Analysis of a Randomized, Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Treatment-Related Acute Myeloid Leukemia (AML) or AML with Myelodysplasia-Related Changes

Geoffrey L. Uy, MD, Jeffrey E. Lancet, MD, Jorge E. Cortes, MD, Laura F. Newell, MD, Tara L. Lin, MD, Ellen K Ritchie, MD, Robert K. Stuart, MD, Stephen A Strickland, Donna Hogge, Scott R Solomon, MD, Richard M. Stone, MD, Dale L. Bixby, Jonathan E. Kolitz, MD, Gary J. Schiller, Matthew J. Wieduwilt, Lynn Shemanski, Michael Chiarella, Arthur C Louie, Bruno C Medeiros, MD

Blood (2017) 130 (Supplement 1): 2647.

https://doi.org/10.1182/blood.V130.Suppl_1.2647.2647

Published: 2017

Journal Articles

Placental Growth Factor (PlGF) Enhances TLR/MK2 Dependent TNF Gene Transcription and Dissociates miRNAs Targeting TNF Regulatory Transcripts from the Polysome

Laura F. Newell, MD, Nicholas Burwick, MD, Christina A Harrington, PhD, Kristina Vartanian, Julja Burchard, Shernan G. Holtan, MD, Akiko Shimamura, MD PhD, Grover C. Bagby, MD

Blood (2016) 128 (22): 408.

https://doi.org/10.1182/blood.V128.22.408.408

Published: 2016

Journal Articles

Analysis of Efficacy By Age for Patients Aged 60-75 with Untreated Secondary Acute Myeloid Leukemia (AML) Treated with CPX-351 Liposome Injection Versus Conventional Cytarabine and Daunorubicin in a Phase III Trial

Blood (2016) 128 (22): 902.

https://doi.org/10.1182/blood.V128.22.902.902

Published: 2016

Journal Articles

Follistatin and Endoglin: Potential Biomarkers of Endothelial Damage and Non-Relapse Mortality after Myeloablative Allogeneic Hematopoietic Cell Transplantation in Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0402

Laura F. Newell, MD, Todd E. DeFor, MS, Corey S. Cutler, MD MPH, Michael R. Verneris, MD, Bruce R. Blazar, MD, Joseph H. Antin, MD, Alan Howard, PhD, Juan Wu, Margaret L. MacMillan, MD, Angela Panoskaltsis-Mortari, PhD, Daniel J. Weisdorf, MD, Shernan G. Holtan, MD

Blood (2016) 128 (22): 63.

https://doi.org/10.1182/blood.V128.22.63.63

Published: 2016

NARROW

A Phase I/II Study to Investigate the Addition of Venetoclax to Dasatinib and Steroids in Patients with Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL): The Venda Trial, in Progress

Prognostic Significance of NCAM1 (CD56) Expression in AML Patients Treated with HMA+Venetoclax

Results of a Phase 1 Trial Testing the Novel Combination Therapy of Venetoclax and Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia Patients

Acute Myeloid Leukemia Differentiation State and Genotype Influence Anti-Apoptotic Protein Expression, Venetoclax Sensitivity, and Survival in AML

Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients Enrolled in CPX-351-301, a Randomized Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk and/or Secondary AML

Phase 3 Exploratory Analysis of Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Received Consolidation with CPX-351 Versus Conventional Chemotherapy

Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Analysis

Outcomes in Patients with Therapy-Related Acute Myeloid Leukemia (t-AML) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Analysis

Feasibility and Cost Analysis of Day 4 Granulocyte Colony-Stimulating Factor Mobilized Peripheral Blood Progenitor Cell Collection from HLA-Matched Sibling Donors

The Impact of Hematopoietic Cell Transplantation on Survival: An Exploratory Analysis of a Phase 3 Study of CPX-351 Versus 7+3 in Older Patients with Newly Diagnosed, High-Risk/Secondary AML

Efficacy and Safety of CPX-351 Versus 7+3 in a Subgroup of Older Patients with Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Enrolled in a Phase 3 Study

Transcriptomal Evidence for Dysregulation of Angiogenic Factors and Inflammatory Markers after Allogeneic Hematopoietic Cell Transplantation

Rates of Adverse Events per Patient-Year in a Randomized, Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, Treatment-Related Acute Myeloid Leukemia (AML) or AML with Myelodysplasia-Related Changes

Amphiregulin Improves Stratification of the Refined Minnesota Acute Graft-Versus-Host Disease Risk Score: Results from BMT CTN 0302/0802

Efficacy and Safety of CPX-351 Versus 7+3 in Older Adults with Secondary Acute Myeloid Leukemia: Combined Subgroup Analysis of Phase 2 and Phase 3 Studies

Subanalysis of Patients with Secondary Acute Myeloid Leukemia (sAML) with Refractory Anemia with Excess of Blasts in Transformation (RAEB-t) Enrolled in a Phase 3 Study of CPX-351 Versus Conventional 7+3 Cytarabine and Daunorubicin

Multivariate Efficacy Analysis of a Randomized, Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Treatment-Related Acute Myeloid Leukemia (AML) or AML with Myelodysplasia-Related Changes

Placental Growth Factor (PlGF) Enhances TLR/MK2 Dependent TNF Gene Transcription and Dissociates miRNAs Targeting TNF Regulatory Transcripts from the Polysome

Analysis of Efficacy By Age for Patients Aged 60-75 with Untreated Secondary Acute Myeloid Leukemia (AML) Treated with CPX-351 Liposome Injection Versus Conventional Cytarabine and Daunorubicin in a Phase III Trial

Follistatin and Endoglin: Potential Biomarkers of Endothelial Damage and Non-Relapse Mortality after Myeloablative Allogeneic Hematopoietic Cell Transplantation in Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0402

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only